Ocular Therapeutix announced its participation in several scientific and investor conferences in July 2026. At the OIS Retina Innovation Summit on July 14, Chief Development Officer Peter K. Kaiser will present on the company's retina experience, and Executive Chairman, President and CEO Pravin U. Dugel will moderate a panel on FDA guidance. At the ASRS 44th Annual Meeting from July 15 to 18, the company will present Phase 3 SOL-1 trial results for its investigational axitinib hydrogel OTX-TKI in wet AMD, along with real-world anti-VEGF treatment analyses and a symposium on redefining nAMD management. Additionally, Dugel will participate in a fireside chat at the HC Wainwright 6th Annual Ophthalmology Virtual Conference on July 22.
Ocular Therapeutix Incpresentation of Phase 3 SOL-1 trial results for OTX-TKI in wet AMD
Advanced Micro Devices Inc